Juyoung Hong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juyoung Hong has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Junho K. Hur
Department of Neurosurgery, Korea University Anam Hospital, Seoul, Korea
3 shared publications - Woochang Hwang
Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul 04763, Republic of Korea
3 shared publications - Hyun Ju Lee
Department of Pediatrics, Hanyang University College of Medicine, Seoul 04763, Republic of Korea
2 shared publications - Suyeon Kang
Department of Biomedical Science, Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, Republic of Korea
2 shared publications - Yong Hun Jang
Department of Pediatrics, College of Medicine, Hanyang University, Seoul 04763, Republic of Korea
2 shared publications - Chul-Kee Park
Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
1 shared publication
Latest Publications
- Open Access
CRISPRi-Mediated Epigenetic Suppression of TERT Reduces Cell Growth in Non-Small-Cell Lung Cancer Cells
TERT, the catalytic subunit of telomerase, is aberrantly activated in most cancers and represents an attractive therapeutic target. However, conventional TERT-targeting strategies, including chemical inhibitors and siRNA, are limited by several issues, such as insufficient efficacy and off-target effects. In this study, we investigated whether dCas9-KRAB-mediated CRISPR interference (CRISPRi) could overcome the limitations by transcriptional repression of TERT without DNA cleavage. We first assessed the efficacy of the dCas9-KRAB system by applying it to H1299 non-small-cell lung cancer cells and observed reduction in TERT expression up to approximately 80% and significant decreases in cell viability and growth. Transcriptome-wide analysis showed limited detectable changes in non-target-gene expression under the conditions tested. Together, the results suggest that dCas9-KRAB-mediated CRISPRi could serve as a proof-of-principle approach for targeted repression of TERT in cancer cells with limited detectable effects on non-target-gene expression.
Open AccessCRISPRi-Mediated Epigenetic Suppression of TERT Reduces Cell Growth in Non-Small-Cell Lung Cancer Cells
TERT, the catalytic subunit of telomerase, is aberrantly activated in most cancers and represents an attractive therapeutic target. However, conventional TERT-targeting strategies, including chemical inhibitors and siRNA, are limited by several issues, such as insufficient efficacy and off-target effects. In this study, we investigated whether dCas9-KRAB-mediated CRISPR interference (CRISPRi) could overcome the limitations by transcriptional repression of TERT without DNA cleavage. We first assessed the efficacy of the dCas9-KRAB system by applying it to H1299 non-small-cell lung cancer cells and observed reduction in TERT expression up to approximately 80% and significant decreases in cell viability and growth. Transcriptome-wide analysis showed limited detectable changes in non-target-gene expression under the conditions tested. Together, the results suggest that dCas9-KRAB-mediated CRISPRi could serve as a proof-of-principle approach for targeted repression of TERT in cancer cells with limited detectable effects on non-target-gene expression.
- Open Access
Oxytocin Modulates Microglial IL-17-Linked Inflammatory Pathways Through the IL-6/COX-2
Neonatal neuroinflammation, driven by microglial activation and cytokine signaling, contributes to brain injury and adverse neurodevelopment outcomes. Perinatal inflammatory mediators, including interleukin-6, cyclooxygenase-2, and interleukin-17, prime microglia and influence circuit vulnerability. This study investigated whether oxytocin pretreatment attenuates lipopolysaccharide-induced inflammatory priming in BV-2 microglial cells. BV-2 microglia were preincubated with oxytocin (33 ng/mL) for 2 h, followed by lipopolysaccharide (0.5 µg/mL) for 2 h. Expression of ionized calcium-binding adapter molecule 1, a microglia marker, in BV-2 cells was assessed by immunofluorescence. After lipopolysaccharide treatment, the gene expression of BV-2 cells was assayed at 1, 2, and 6 h post stimulation by RT-qPCR and RNA-seq. Functional characterization of gene expression profile was performed. Analyses of gene expression profile of BV-2 cells by RT-qPCR and RNA-seq revealed that oxytocin pretreatment attenuated lipopolysaccharide-induced transcriptional activation, including interleukin-6 and cyclooxygenase-2 upregulation. Pathway enrichment analyses suggested that oxytocin-responsive genes were linked to the interleukin-17 signaling pathway. Gene Ontology enrichment analysis showed enrichment for genes related to cytokine production, membrane raft, and chemokine activity. Oxytocin pretreatment mitigates lipopolysaccharide-induced microglial activation by modulating the interleukin-17–interleukin-6/cyclooxygenase-2 axis, suggesting its potential role for oxytocin as an endogenous modulator of neuroinflammation during early brain development.
Open AccessOxytocin Modulates Microglial IL-17-Linked Inflammatory Pathways Through the IL-6/COX-2
Neonatal neuroinflammation, driven by microglial activation and cytokine signaling, contributes to brain injury and adverse neurodevelopment outcomes. Perinatal inflammatory mediators, including interleukin-6, cyclooxygenase-2, and interleukin-17, prime microglia and influence circuit vulnerability. This study investigated whether oxytocin pretreatment attenuates lipopolysaccharide-induced inflammatory priming in BV-2 microglial cells. BV-2 microglia were preincubated with oxytocin (33 ng/mL) for 2 h, followed by lipopolysaccharide (0.5 µg/mL) for 2 h. Expression of ionized calcium-binding adapter molecule 1, a microglia marker, in BV-2 cells was assessed by immunofluorescence. After lipopolysaccharide treatment, the gene expression of BV-2 cells was assayed at 1, 2, and 6 h post stimulation by RT-qPCR and RNA-seq. Functional characterization of gene expression profile was performed. Analyses of gene expression profile of BV-2 cells by RT-qPCR and RNA-seq revealed that oxytocin pretreatment attenuated lipopolysaccharide-induced transcriptional activation, including interleukin-6 and cyclooxygenase-2 upregulation. Pathway enrichment analyses suggested that oxytocin-responsive genes were linked to the interleukin-17 signaling pathway. Gene Ontology enrichment analysis showed enrichment for genes related to cytokine production, membrane raft, and chemokine activity. Oxytocin pretreatment mitigates lipopolysaccharide-induced microglial activation by modulating the interleukin-17–interleukin-6/cyclooxygenase-2 axis, suggesting its potential role for oxytocin as an endogenous modulator of neuroinflammation during early brain development.
- Open Access
- 4 November 2025
- Published by MDPI AG in Preprints.org
Oxytocin Modulates Microglial IL-17-Linked Inflammatory Pathways Through the IL-6/COX-2
Background: Neonatal neuroinflammation, driven by microglial activation and cytokine signaling, contributes to brain injury and adverse neurodevelopment outcomes. Perinatal inflammatory mediators, including IL-6, COX-2, and IL-17, prime microglia and influence circuit vulnerability. This study investigated whether oxytocin (OT) pretreatment attenuates lipopolysaccharide (LPS)-induced inflammatory priming in BV-2 microglial cells. Methods: BV-2 microglia were preincubated with OT (33ng/mL) for 2 hours, followed by LPS (0.5 µg/mL) for 2 hours. Expression of IBA1, a microglia marker, in BV-2 was assessed by immunofluorescence. After LPS treatment, the gene expression of BV-2 cells was assayed 2 and 6 hours post-LPS stimulation by RT-qPCR and RNA-seq. Functional characterization of gene expression profile was performed with KEGG and GO analyses. Results: Analyses of gene expression profile of BV-2 cells by RT-qPCR and RNA-seq revealed that OT pretreatment attenuated LPS-induced transcriptional activation, including IL-6 and COX-2 upregulation. KEGG pathway enrichment analyses suggested that OT-responsive genes were linked to the IL-17 signaling pathway. GO analyses showed enrichment for genes related to cytokine production, membrane raft, and chemokine activity. Conclusions: OT pretreatment mitigates LPS-induced microglial activation by modulating the IL-17–IL-6/COX-2 axis, suggesting its potential role for OT as an endogenous modulator of neuroinflammation during early brain development.
- 4 November 2025
- Published by MDPI AG in Preprints.org
Open AccessOxytocin Modulates Microglial IL-17-Linked Inflammatory Pathways Through the IL-6/COX-2
Background: Neonatal neuroinflammation, driven by microglial activation and cytokine signaling, contributes to brain injury and adverse neurodevelopment outcomes. Perinatal inflammatory mediators, including IL-6, COX-2, and IL-17, prime microglia and influence circuit vulnerability. This study investigated whether oxytocin (OT) pretreatment attenuates lipopolysaccharide (LPS)-induced inflammatory priming in BV-2 microglial cells. Methods: BV-2 microglia were preincubated with OT (33ng/mL) for 2 hours, followed by LPS (0.5 µg/mL) for 2 hours. Expression of IBA1, a microglia marker, in BV-2 was assessed by immunofluorescence. After LPS treatment, the gene expression of BV-2 cells was assayed 2 and 6 hours post-LPS stimulation by RT-qPCR and RNA-seq. Functional characterization of gene expression profile was performed with KEGG and GO analyses. Results: Analyses of gene expression profile of BV-2 cells by RT-qPCR and RNA-seq revealed that OT pretreatment attenuated LPS-induced transcriptional activation, including IL-6 and COX-2 upregulation. KEGG pathway enrichment analyses suggested that OT-responsive genes were linked to the IL-17 signaling pathway. GO analyses showed enrichment for genes related to cytokine production, membrane raft, and chemokine activity. Conclusions: OT pretreatment mitigates LPS-induced microglial activation by modulating the IL-17–IL-6/COX-2 axis, suggesting its potential role for OT as an endogenous modulator of neuroinflammation during early brain development.